| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8178554 | ALLERGAN | Heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents |
Jul, 2021
(2 years ago) | |
| US7112592 | ALLERGAN | Azabicyclic compounds, preparation thereof and use as medicines, in particular as antibacterial agents |
Jan, 2026
(1 year, 8 months from now) | |
| US8471025 | ALLERGAN | Crystalline forms of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide sodium salt |
Aug, 2031
(7 years from now) | |
| US9695122 | ALLERGAN | Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof |
Jun, 2032
(8 years from now) | |
| US8969566 | ALLERGAN | Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof |
Jun, 2032
(8 years from now) | |
| US9284314 | ALLERGAN | Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof |
Jun, 2032
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7612087 | ALLERGAN | Heterocyclic compounds as inhibitors of beta-lactamases |
Nov, 2026
(2 years from now) | |
| US8835455 | ALLERGAN | Crystalline forms of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide sodium salt |
Oct, 2030
(6 years from now) | |
Avycaz is owned by Allergan.
Avycaz contains Avibactam Sodium; Ceftazidime.
Avycaz has a total of 8 drug patents out of which 1 drug patent has expired.
Expired drug patents of Avycaz are:
- US8178554
Avycaz was authorised for market use on 25 February, 2015.
Avycaz is available in powder;intravenous dosage forms.
Avycaz can be used as method of treating bacterial infections, a method of treating a bacterial infection in hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (habp/vabp) patients comprising administering an effective amount of avibactam sodium.
Drug patent challenges can be filed against Avycaz from 26 February, 2024.
The generics of Avycaz are possible to be released after 15 June, 2032.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 25, 2020 |
| New Patient Population(NPP) | Dec 20, 2025 |
| Generating Antibiotic Incentives Now(GAIN) | Feb 25, 2025 |
| New Indication(I-738) | Jun 22, 2019 |
Drugs and Companies using AVIBACTAM SODIUM; CEFTAZIDIME ingredient
NCE-1 date: 26 February, 2024
Market Authorisation Date: 25 February, 2015
Treatment: A method of treating a bacterial infection in hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (habp/vabp) patients comprising administering an effective amount of a...
Dosage: POWDER;INTRAVENOUS
AVYCAZ family patents
